Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
Not yet recruiting · NCT06956092 · Registry updated 2025-05-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 4 | 2025-05-02 | NCT06956092 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Zhengzhou University | 21 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The First Affiliated Hospital of Zhengzhou University, Department of Oncology | Zhengzhou | China | 3 |